Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Because the RSV vaccine was ultimately approved for administration during a narrower gestational age window than was ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

The same doctors who used that drug for the first time in the world are now testing another drug to help people who suffer a ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...